The outlook of companies tied to Viagra's history presents a challenging investment picture . While the initial boom generated substantial gains, generic copies have significantly eroded market share . Investing in associated pharmaceutical businesses now requires a thorough assessment of intellectual property safeguards, evolving medical changes,